Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 5/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.31 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.31 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1991847 | 0.89 | SMN1; SMN2 (0.40) | TP53HTTSMN1; SMN2NPSR1CYP3A4 | |
| SCHEMBL1990367 | 0.84 | TP53 (0.36) | SCN9AIDO1GRIA2TP53HTT | |
| SCHEMBL1993594 | 0.82 | NAMPT (0.44) | HTTSMN1; SMN2NPSR1LMNA | |
| SCHEMBL3265259 | 0.82 | IDO1 (0.36) | SCN9AIDO1TP53HTTSMN1; SMN2 | |
| SCHEMBL1989372 | 0.82 | CYP19A1 (0.38) | SCN9AIDO1GRIA2TP53KAT5 | |
| SCHEMBL1992284 | 0.82 | CYP11B2 (0.45) | SMN1; SMN2LMNA | |
| SCHEMBL1992887 | 0.82 | CYP3A4 (0.40) | SMN1; SMN2CYP3A4 | |
| SCHEMBL1988741 | 0.82 | CYP3A4 (0.43) | TP53HTTSMN1; SMN2NPSR1CYP3A4 | |
| SCHEMBL1993635 | 0.82 | CNR1 (0.38) | SCN9A | |
| SCHEMBL1989364 | 0.82 | KMT2A (0.42) | SCN9AGRIA2SMN1; SMN2CYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152236-A1 | AZETIDINE POLYSUBSTITUTED COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2011-06-23 | — | — | US | claimed |
| US-20110152236-A1 | AZETIDINE POLYSUBSTITUTED COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152236-A1 | AZETIDINE POLYSUBSTITUTED COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | C1R, TACR1, C1S | SCN9A 304/4885IDO1 559/4885GRIA2 2659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.